Phase 1 Study to Evaluate the Effect of DS-8201a on the QT/QTc Interval and Pharmacokinetics in HER2-Expressing Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Malignant Neoplasm of Breast
Interventions: DRUG: DS-8201a
Sponsor: Daiichi Sankyo Co., Ltd.
Collaborators: AstraZeneca